Investigational oral regimen for hepatitis C shows promise in NIH trial
In a study of an all-oral drug regimen, a majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, ...
Aug 27, 2013
0
0